Primary Membranous News Today

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

Positive phase 2 data from 2 studies on the investigational monoclonal antibody felzartamab designed to deplete CD38+ plasma cells, demonstrated reduced pathogenic antibody levels in primary membranous nephropathy.

Research into some of the world’s rarest forms of cancer and disease have received a boost, with the Morrison Government announcing 27 grant